DCVAC/LuCa

Drug Profile

DCVAC/LuCa

Alternative Names: Dendritic cell vaccine/Lung cancer - Sotio

Latest Information Update: 06 Apr 2017

Price : $50

At a glance

  • Originator SOTIO
  • Class Cancer vaccines; Cell therapies; Dendritic cell vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Non-small cell lung cancer

Most Recent Events

  • 06 Apr 2017 DCVAC/LuCa is still in phase I/II trials for Non-small cell lung cancer in Czech Republic and Slovakia (SC)
  • 30 Nov 2014 Phase-I/II clinical trials in Non-small cell lung cancer (First-line therapy, Combination therapy, Late-stage disease) in Czech Republic (SC)
  • 30 Nov 2014 Phase-I/II clinical trials in Non-small cell lung cancer (First-line therapy, Combination therapy, Late-stage disease) in Slovakia (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top